Figure 7.
Inhibition of secondary tumors by Ad5mTR.sPD1 treatment. (a) CT26 tumors were implanted subcutaneously in BALB/c mice and then injected intratumorally with 5 × 108 plaque forming units of Ad5mTR.sPD1 three times at 3-day intervals. Two weeks after the initial treatment, the opposite flank was challenged with 1 × 106 tumor cells. Ganciclovir (75 mg/kg) was administered intraperitoneally during virus treatment starting 1 day after the first virus injection and continuing for 12 days. Tumor size was calculated every 3 days. (b) E.G7 tumors were implanted subcutaneously in C57/BL6 mice and then treated as described for (a). (c) On day 7 after the second secondary challenge, tumor size at the challenge site in mice previously treated with Ad5mTR.sPD1 or in untreated mice was measured. Data represent the mean ± SD. Avg, average.